Centauri Therapeutics, a British immunotherapy company, has received an $8.1 million investment from the AMR Action Fund to support development of its broad-spectrum antibiotic candidate. CIDRAP has the news.
The money will “help support the completion of phase 1 clinical studies for CTX-187, a novel antibiotic that employs a dual-mechanism action to target clinically prevalent and multidrug-resistant gram-negative bacteria. The drug is built on Centauri's Alphamer platform, which harnesses the immune system to target pathogenic bacteria.”
AMR Action Fund is a venture capital fund “focused on development of novel antimicrobial therapeutics for priority pathogens.” Centauri’s CEO said the investment enabled a “clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset.” The fund was launched in 2020 with the aim of investing $1 billion in “small and mid-sized biotech companies with promising antimicrobial products.”
Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care.